US health officials issued a statement expressing concern that AstraZeneca may have included outdated information from its US coronavirus vaccine trials, which “may have provided an incomplete view of the efficacy data.” The statement follows AstraZeneca’s publication of late-stage US clinical trial data, which found the vaccine to be 79% effective. AstraZeneca’s vaccine has not yet received US regulatory authorization, and additional detail on the health officials’ concerns was not provided.
More context: The statement was issued by the National Institute of Allergy and Infectious Diseases (NIAID), which was notified of the potential issue by the Data and Safety Monitoring Board (DSMB). Read it here.
The New Paper
This story is from the March 23, 2021 edition of The New Paper – a clear, concise daily briefing that makes fact-first news easy to consume. Try it today.
